[go: up one dir, main page]

WO2013034780A3 - Process for the preparation of estetrol and related compounds - Google Patents

Process for the preparation of estetrol and related compounds Download PDF

Info

Publication number
WO2013034780A3
WO2013034780A3 PCT/EP2012/076358 EP2012076358W WO2013034780A3 WO 2013034780 A3 WO2013034780 A3 WO 2013034780A3 EP 2012076358 W EP2012076358 W EP 2012076358W WO 2013034780 A3 WO2013034780 A3 WO 2013034780A3
Authority
WO
WIPO (PCT)
Prior art keywords
estetrol
preparation
formula
related compounds
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/076358
Other languages
French (fr)
Other versions
WO2013034780A2 (en
Inventor
Juan José FERREIRO GIL
Jesús Miguel IGLESIAS RETUERTO
Francisco Javier GALLO NIETO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curia Spain SA
Original Assignee
Crystal Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharma SA filed Critical Crystal Pharma SA
Priority to PCT/EP2012/076358 priority Critical patent/WO2013034780A2/en
Publication of WO2013034780A2 publication Critical patent/WO2013034780A2/en
Publication of WO2013034780A3 publication Critical patent/WO2013034780A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a process for obtaining Estetrol and derivatives thereof of formula (I) or a salt or solvate thereof, wherein R represents H or anhydroxyl protecting group; the process comprising reacting a compound of formula (II) or a salt or solvate thereof, wherein R is as defined previously, with an oxidizing agent; the invention also relates to said 3-OH protected derivatives of formula (I) and intermediate products useful in the process.
PCT/EP2012/076358 2012-12-20 2012-12-20 Process for the preparation of estetrol and related compounds Ceased WO2013034780A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076358 WO2013034780A2 (en) 2012-12-20 2012-12-20 Process for the preparation of estetrol and related compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076358 WO2013034780A2 (en) 2012-12-20 2012-12-20 Process for the preparation of estetrol and related compounds

Publications (2)

Publication Number Publication Date
WO2013034780A2 WO2013034780A2 (en) 2013-03-14
WO2013034780A3 true WO2013034780A3 (en) 2013-10-03

Family

ID=47435979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/076358 Ceased WO2013034780A2 (en) 2012-12-20 2012-12-20 Process for the preparation of estetrol and related compounds

Country Status (1)

Country Link
WO (1) WO2013034780A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924255C (en) * 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
HU231240B1 (en) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Industrial process for the preparation of high-purity estetrol
ES2915058B2 (en) * 2019-09-27 2024-06-21 Ind Chimica Srl Process to prepare (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (Estetrol) and intermediates of said process
IT201900017414A1 (en) * 2019-09-27 2021-03-27 Ind Chimica Srl Process for the preparation of (15α, 16α, 17β) -estra-1,3,5 (10) -trene-3,15,16,17-tetrol (Estetrol) and intermediates of said process
IT202100019631A1 (en) 2021-07-23 2023-01-23 Newchem S P A METHOD FOR PRODUCING ESTETROL AND ITS INTERMEDIATE
WO2023021026A1 (en) 2021-08-17 2023-02-23 Aspen Oss B.V. A synthetic pathway to estra-1,3,5(10)-triene-3,15a,16a,17b-tetrol
US20240391947A1 (en) * 2021-10-01 2024-11-28 Industriale Chimica S.R.L. PROCESS FOR PREPARING (15alpha,16alpha,17beta)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) AND ESTETROL MONOHYDRATE
ES3036185A2 (en) 2023-02-02 2025-09-15 Ind Chimica Srl PREPARATION PROCESS OF (15alpha,16alpha,17beta)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL MONOHYDRATE (ESTETROL)
CN119569803B (en) * 2023-09-05 2025-09-16 秦皇岛紫竹药业有限公司 A method for preparing high-purity estetrol
HUP2400151A1 (en) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Process for the crystallization of estetrol monohydrate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041839A2 (en) * 2002-11-08 2004-05-21 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
EP2383279A1 (en) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2013050553A1 (en) * 2011-10-07 2013-04-11 Estetra S.A. Process for the production of estetrol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1390042E (en) 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ES2337129T3 (en) 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. MEDICINAL ADMINISTRATION SYSTEM UNDERSTANDING A TETRAHYDROXYLED STROGEN FOR USE IN HORMONAL ANTI-CONCEPTION.
ATE347365T1 (en) 2001-11-15 2006-12-15 Pantarhei Bioscience Bv USE OF ESTROGEN IN COMBINATION WITH PROGESTOGEN FOR HORMONE SUBSTITUTION THERAPY
CN1691947B (en) 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 Application of estrogen component in preparation for treatment or prevention of immune-mediated diseases and pharmaceutical composition comprising said estrogen component
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
CN100374116C (en) 2002-07-12 2008-03-12 潘塔希生物科学股份有限公司 Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
CA2674325A1 (en) 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041839A2 (en) * 2002-11-08 2004-05-21 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
EP2383279A1 (en) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2013050553A1 (en) * 2011-10-07 2013-04-11 Estetra S.A. Process for the production of estetrol

Also Published As

Publication number Publication date
WO2013034780A2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013034780A3 (en) Process for the preparation of estetrol and related compounds
CA2826751C (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
WO2010105179A3 (en) Inhibitors of beta-secretase
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
NZ707389A (en) Process for preparing bile acid derivatives
WO2014100764A3 (en) Methods of inhibiting prmt5
PH12016500169A1 (en) Polymorph of syk inhibitors
WO2011141110A3 (en) Photo-stabilizing agents
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
WO2011012816A3 (en) Pharmaceutical formulation
WO2012004396A3 (en) Process of preparing a thrombin specific inhibitor
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2014054058A8 (en) Novel compounds, their synthesis and their uses
WO2012117357A3 (en) Process for preparation of ketolide intermediates
BRPI1007414A2 (en) thiadiazole and oxadiazole derivatives, their preparation and their application in therapeutic
WO2014036502A3 (en) Tetracycline compounds
WO2014017938A3 (en) Process for the synthesis of substituted urea compounds
WO2013128419A3 (en) Pharmaceutical compositions comprising boronic acid compounds
WO2012038979A3 (en) A process for preparation of ertapenem
UA116877C2 (en) Novel derivatives of hemin with antibacterial and antiviral activity
WO2011007136A3 (en) Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein
WO2013096697A3 (en) Isolation, identification, and used of antifungal compounds
DK2870141T3 (en) METHANTHION COMPOUNDS WITH ANTIVIRUS ACTIVITY
PH12015501056A1 (en) 2-pyridone compound
WO2013062332A3 (en) Vascular anti-aging composition including syringaresinol

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 12806471

Country of ref document: EP

Kind code of ref document: A2